Rapid Dose Therapeutics to go public on CSE

ACME Resources Corp. has filed a non-offering preliminary prospectus for the purpose of qualifying Acme Resources for listing on the Canadian Securities Exchange (CSE).

ACME Resources intends to apply for a listing of its common shares on the CSE.

ACME Resources was originally listed as a capital pool company and most recently traded on the NEX Tier of the TSX Venture Exchange under the symbol ACY.H. Its shares were delisted from NEX on March 28, 2018.

On April 9, 2018, ACME Resources signed the definitive agreement with Rapid Dose Therapeutics Inc. (RDT) for or a three-cornered amalgamation transaction which would constitute a proposed reverse take-over of ACME by RDT.

Vancouver based Rapid Dose Therapeutics is a Canadian pharma-technology company that provides proprietary oral and non-invasive drug delivery technologies designed for applications of nutraceuticals, active pharmaceutical ingredients, and other healthcare products. RDT provides product innovation, production, and consultation to the pharmaceutical and healthcare manufacturing industry.

Rapid Dose Therapeutics is led by CEO & Director Mark Upsdell, and SVP & Director, Jason Lewis, who are the two largest shareholders.

photo credit: RDT

Ted Liu

Ted Liu, M.Sc. (Mining, Queen's), MBA (Finance, Toronto), is the Editor of Private Capital Journal, CanadaMetals.ca, TechWire.ca, and the former Editor of Canadian Private Equity. Ted has been passionately tracking Canadian private capital industry since 1992, having most recently served as Research Director for The Canadian Venture Capital and Private Equity Association (CVCA).

Ted is the architect of CVCA infobase, and is the architect of CPE Media's Financings.ca, Canada's most sophisticated and advanced all private capital and public market financing database.